UNSPSC 51386017: Zoliprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H11NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2GC047H27, chemically known as propionic acid, 2-(p-((2-thiazolyl)oxy)phenyl)- but generally known as zoliprofen, which bears US NIH Compound Identifier 68758. European Medicines Agency schedules Zoliprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00180MIG.

UNSPSC 51386017 Zoliprofen is a Commodity code, but the recent state and local opportunities posted under it involve naloxone, drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—not zoliprofen specifically. The code shows a mismatch between its nominal scope and the work actually being solicited. State and local governments are using this code tag to procure opioid-reversal agents, pharmacy benefit program administration, and generic pharmaceutical supply agreements, suggesting either a data-classification inconsistency in the source or that the code has been repurposed to cover a broader family of pharmaceutical procurement activities.

The issuing bodies span county health departments, state HHS commissions, and cooperative purchasing alliances. Seminole County, Florida (IFB60459723LAS, posted June 30, 2026, response due July 26, 2023) is seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802, posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, through three authorized wholesalers. Recent activity clusters in Florida, Texas, and Minnesota, with multi-state cooperative purchasing extending into the Pacific Northwest. The MMCAP opportunity requires vendor certification under current Good Manufacturing Practices and the Drug Supply Chain Security Act, pricing submission in multiple formats, and a 3 percent administrative fee on all contract purchases. No recent opportunities have been posted demonstrating zoliprofen procurement itself under this code.